ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to rethink their income strategy completely.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
AbbVie (NYSE:ABBV | ABBV Price Prediction) or Johnson & Johnson (NYSE:JNJ): which healthcare dividend is the better stock for a retirement portfolio right now? Both trade near their 52-week highs. AbbVie is at $266.58 against a high of $269.39, and Johnson & Johnson trades at $270.68. Over the past year, investors paid up for J&J’s diversity, sending shares 56.64% higher versus AbbVie’s 24.94%. Income investors need to consider which payout holds up better over the next decade.
Growth Trajectory: AbbVie Wins on Speed and Price
AbbVie’s second-quarter revenue rose 10.2% to $16.99 billion. Immunology did the heavy lifting: Skyrizi hit $5.51 billion (+24.4%) and Rinvoq reached $2.53 billion (+24.5%). Humira fell to $756 million (-35.9%), yet management still raised full-year revenue guidance to approximately $67.6 billion.
J&J grew second-quarter sales 5.6% operationally to $25.3 billion, absorbing a 460 basis point headwind from Stelara. Its reported growth midpoint of 7.3% also includes a 53rd-week benefit of about 100 basis points.
AbbVie is also cheaper: 16x forward earnings versus 21x for J&J, with a PEG ratio of 0.542 against 2.823. Faster growth at a lower multiple gives AbbVie this round.
Yield and Income: AbbVie Pays More and Raises Faster
AbbVie yields 2.58% on a forward annual dividend of $6.92. Its most recent raise was 5.5% to $1.73 per quarter, and the payout has rose every year in the record, from $0.40 in 2013 to today’s level.
J&J yields 1.95% on a forward dividend of $5.36. Its latest raise was 3.1% to $1.34, which the company says marks 64 consecutive years of increases. Payment records back to 1999, when the quarterly payout was $0.25, confirm annual raises across that span. On current income and raise velocity, AbbVie wins.
Risk and Payout Durability: Johnson & Johnson Wins Decisively
The retirement portfolio decision comes down to this. J&J has 28 products and platforms each generating more than $1 billion annually. CFO Joe Wolk put it simply: “We are not dependent on one or two products.” The company carries a AAA credit rating, produced $19.7 billion in free cash flow in 2025, and expects 2026 free cash flow approaching $21 billion. Adjusted EPS guidance of $11.45 to $11.65 well covers the $5.36 forward dividend. Litigation charges ($330 million in Q1) and the Orthopaedics separation are real but manageable risks.
AbbVie’s payout rests on a narrower base. Skyrizi’s composition of matter patent expires in 2033, and the company is funding the $10.9 billion Apogee deal with new debt. Management says it remains “committed to achieving a net leverage ratio of two times within two to three years following the deal close.” Book value stands at -$3.359 per share, and trailing GAAP EPS of $3.55 runs below the $6.83 trailing dividend because of acquired R&D charges. Adjusted EPS guidance of $13.87 to $14.07 covers the payout, but AbbVie has already replaced one blockbuster and must do it again. J&J’s beta of 0.235 also edges AbbVie’s 0.281.
Verdict: Johnson & Johnson for Retirees Living on the Check
For retirees who depend on dividend income today, Johnson & Johnson is the stronger core holding. The lower yield is the price of a payout backed by 28 billion-dollar franchises, roughly $21 billion of expected free cash flow, and a AAA balance sheet. That structure survives a single drug tripping up.
AbbVie wins for investors still a decade or more from retirement who want faster income growth and a cheaper multiple, and who can tolerate concentration in two immunology drugs. Watch J&J’s Enterprise Business Review on December 8 and AbbVie’s Skyrizi Crohn’s decision, expected “later this fall.”
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
